First approved in 2017, Imfinzi was previously available in the U.S. as a combination therapy for treating metastatic NSCLC. More on AstraZeneca AstraZeneca PLC (AZN) Q2 2024 Earnings Call Transcript ...

Imfinzi is a key revenue driver for AZN’s oncology portfolio, having generated sales worth $2.26 billion in the first half of 2024, up 25% year over year at constant exchange rates.

Imfinzi won approval for use in mid-stage non-small cell lung cancer a year later. In March 2020, the FDA approved Imfinzi to target extensive-stage small-cell lung cancer.

AstraZeneca’s Imfinzi (durvalumab) in combination with chemotherapy has been approved by the Food and Drug Administration for the treatment of adult patients with resectable early-stage (IIA ...

References: Imfinzi ® (durvalumab) plus chemotherapy approved in the US for mismatch repair deficient advanced or recurrent endometrial cancer. News release. AstraZeneca. June 17, 2024. https ...

BARCELONA, Spain — An AstraZeneca immunotherapy, given both before and after surgery, improved survival rates in patients with bladder cancer, results that could reshape how muscle-invasive ...

IMFINZI® (durvalumab) plus chemotherapy more than doubled pathologic complete response rate in resectable early-stage gastric and gastroesophageal junction cancers versus chemotherapy alone ...

NIAGARA is a randomized, open-label, multi-center, global Phase III trial evaluating perioperative IMFINZI as treatment for patients with MIBC before and after radical cystectomy.

This approval is based on late-stage study data, which shows that treatment with AstraZeneca's (AZN) Imfinzi reduced the risk of recurrence by 32% in certain non-small cell lung cancer patients.

NIAGARA is a randomized, open-label, multi-center, global Phase III trial evaluating perioperative IMFINZI as treatment for patients with MIBC before and after radical cystectomy.